Cancer Drugs– tag –

In this article, we summarize the phase 1 trial of IBI343, reported in Nature Medicine (July 2025), focusing on its structural innovations, safety, efficacy, and position within the landscape of Claudin18.2-targeted ADCs. Drug Profile: M...

In a nutshell: Genome-wide CRISPR screens in patient-derived gastric cancer organoids uncovered strong dependencies on fatty-acid biosynthesis (ACC/ACACA) and cholesterol biosynthesis (LSS). Co-culture with enteric neurons (ENS) rewires ...

In Part 1 of our feature, we explored Enhertu’s groundbreaking pharmacological profile and its role in launching the second ADC boom. In this concluding part, we shift focus to intellectual property strategies, patent lifespans, and the ...

Antibody–drug conjugates (ADCs) targeting Claudin18.2 (CLDN18.2) have gained increasing attention as a novel therapeutic approach for advanced gastric and gastroesophageal junction (GEJ) cancers. Here, we summarize the phase 1 trial resu...

Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergo...

This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli...

Across pancreatic ductal adenocarcinoma (PDAC) models, tumor cells show marked intercellular heterogeneity in stress granules (SGs). A single-cell, cell-cycle–aware view reveals that SGs are maximally enriched in G2, powered by a lipid m...

Last updated: 2025-09-01 JST What you will learn Three-Line SummaryWhy in vivo (now)?Company Highlights (Q3 2025)Two Paths, One GoalClinical KPIs to Watch Lead: The shift from ex vivo to in vivo CAR-T is turning into a full-blown race. B...

Appendix: IL-6R Inhibitors & Company Landscape (as of Aug 2025) A quick map of who owns which IL-6R blockers and current approved uses, to inform combo trials and partnering around the neuro-immune loop discussed above. What you will...

Introduction: A New Relationship Between Transcription Factors and DNA Repair Recent cancer research has highlighted DNA replication errors and defects in repair mechanisms as central drivers of tumorigenesis. The mismatch repair (MMR) s...

Fresh data in Science Signaling (2025) show that tumor-derived small extracellular vesicles (sEVs) reprogram TRPV1+ nociceptors, boosting IL-6 and Substance P, thereby increasing MDSC infiltration and CD8 T-cell exhaustion—a neuro-immune...

Trilogy Subtitles＋Series Summary Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generatio...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...

This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Dru...

In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. In this final deep-dive of our beginner-friendly bispecific antibody series, we e...

Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significa...

In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we delve into the crucial question: “Which targets should be selec In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we...